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Key Points




HMB is associated
with rare and common
variants in genes
related to anemias
and bleeding
disorders.
These are the ﬁrst
exome-sequencing
results from patients
with HMB, as well as
their comparison with
control exomes.

Adolescents with low von Willebrand factor (VWF) levels and heavy menstrual bleeding
(HMB) experience signiﬁcant morbidity. There is a need to better characterize these
patients genetically and improve our understanding of the pathophysiology of bleeding.
We performed whole-exome sequencing on 86 postmenarchal patients diagnosed with
low VWF levels (30-50 IU/dL) and HMB and compared them with 660 in-house controls.
We compared the number of rare stop-gain/stop-loss and rare ClinVar “pathogenic”
variants between cases and controls, as well as performed gene burden and gene-set
burden analyses. We found an enrichment in cases of rare stop-gain/stop-loss variants in
genes involved in bleeding disorders and an enrichment of rare ClinVar “pathogenic”
variants in genes involved in anemias. The 2 most signiﬁcant genes in the gene burden
analysis, CFB and DNASE2, are associated with atypical hemolytic uremia and severe
anemia, respectively. VWF also surpassed exome-wide signiﬁcance in the gene burden
analysis (P 5 7.31 3 1026). Gene-set burden analysis revealed an enrichment of rare
nonsynonymous variants in cases in several hematologically relevant pathways. Further,
common variants in FERMT2, a gene involved in the regulation of hemostasis and
angiogenesis, surpassed genome-wide signiﬁcance. We demonstrate that adolescents
with HMB and low VWF have an excess of rare nonsynonymous and pathogenic variants
in genes involved in bleeding disorders and anemia. Variants of variable penetrance in
these genes may contribute to the spectrum of phenotypes observed in patients with
HMB and could partially explain the bleeding phenotype. By identifying patients with
HMB who possess these variants, we may be able to improve risk stratiﬁcation and
patient outcomes.
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Introduction

Although there have been several genome-wide association studies
(GWAS) of VWF levels,13-17 as well as GWAS of hematological
parameters, such as number and volume of various cell types in
blood,18-20 these do not detect associations with rare variants. One
study validated 1 of the top hits from these GWAS and found that
homozygosity for a SNP in TMPRSS6 was protective against IDA,
especially in women with HMB.21 To date, no next-generation
sequencing study has speciﬁcally looked at genetic risk factors for
HMB. Although it might be expected that such a study would ﬁnd
an excess of rare and pathogenic variants in the VWF gene in this
population of patients with low VWF, by taking an agnostic
approach, other genetic patterns may emerge. Here, we describe
the results from the ﬁrst whole-exome sequencing of 86 adolescent
patients with HMB and low VWF, as well as comparison with 660
unrelated control exomes.

Methods
Subjects and samples
A multicenter observational cohort study to delineate the phenotype
and genotype of adolescent females with low VWF–associated
HMB was undertaken from February of 2017 to June of 2019. Tertiary care centers in North America, with expertise in hemostasis
and that provided care for adolescents with HMB and were members of the Foundation for Women and Girls with Blood Disorders,
participated in the study. Institutional Review Board approval was
obtained by all participating centers, and parental and/or patient
consent/assent was obtained from all patients prior to study participation. Ten centers participated in this multicenter study. One hundred and thirteen adolescent females with a diagnosis of HMB and
low VWF, who met the study inclusion and exclusion criteria, were
enrolled. One patient was withdrawn because of the subsequent
detection of type 1 VWD and factor XI deﬁciency. The clinical and
laboratory characteristics of this cohort were published recently.12
Of the 113 patients enrolled, 86 had sufﬁcient blood samples collected for whole-exome sequencing and formed the study population for this analysis.

Eligibility criteria
The study eligibility criteria included postmenarchal females, ,21
years of age who were diagnosed with HMB, deﬁned as a Pictorial
25 JANUARY 2022 • VOLUME 6, NUMBER 2

Sequencing analysis and validation
Exome sequence data for 86 unrelated HMB probands and 660
unrelated in-house controls were generated at the McDonnell
Genome Institute (Washington University in St. Louis) using IDT
xGen Exome Panel V1 capture on Illumina HiSeq 4000 paired-end
reads. The average age of the controls was 16, with a range of 3 to
40 years. Fifty-seven percent of controls (376/660) were female.
Analysis of exome sequencing data was performed in-house using
our previously described methods,22,23 with the addition of the Sentieon software package. Brieﬂy, FASTQ formatted sequences were
aligned to the hg19 human reference sequence (NCBI GRCh37)
using Burrows-Wheeler Aligner (BWA).24 Mapped reads were ﬁltered to remove duplicate reads with the same paired start sites.
Median depth per sample at captured bases for HMB cases was
763 (range, 17-202); it was 713 (range, 21-121) for in-house controls. All cases and controls had .97% of captured bases covered
with .10 reads. The Binary sequence Alignment/Map formatted
alignments were processed using the Genome Analysis Toolkit
(GATK) Haplotype Caller25,26 and genotypes jointly called together
with all in-house control exome-sequenced individuals. Genotypes
were ﬁltered for read depth (.103), genotype quality . 20, and
allele balance . 0.3 and ,0.7. Variants were ﬁltered for GATKcalculated variant quality score recalibration and genotype call rate
.90%. Allele frequencies were annotated using the gnomAD database.27 Variants were functionally annotated using ANNOVAR.28 To
reduce the risk of population stratiﬁcation, only cases and controls
with principal components–conﬁrmed European ancestry were
included in all analyses. Principal components were calculated using
EIGENSTRAT29 from whole-exome single-nucleotide polymorphism
(SNP) data using all common (minor allele frequency [MAF] . 5%)
SNPs. We did not remove any cases, because principal components conﬁrmed self-reported race. For the purposes of all single
SNP analyses, the standard cutoffs for genome-wide signiﬁcance
(5 3 1028) and exome-wide signiﬁcance (2.5 3 1026) were used.
We reasonably excluded HMB and low VWF from the control
cohort because the estimate of the prevalence of low VWF–
associated HMB in the general population is likely 1% given that
the prevalence of low VWF is generally 2.5% and the prevalence
of HMB is 35%.4,30,31
EXOME DATA IDENTIFY NOVEL ASSOCIATIONS WITH HMB
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Heavy menstrual bleeding (HMB) is a pathologic state deﬁned as
excessive or prolonged menstrual blood loss . 80 mL per menstrual cycle1-3; it occurs in approximately one third of adolescent
females.4,5 Quality of life can be signiﬁcantly affected by HMB, in
the form of signiﬁcant iron deﬁciency anemia (IDA), psychological
distress, missed school, limitations on activities, and prolonged periods of required rest.6,7 The co-occurrence of bleeding disorders in
this population has been shown to be higher than in the general
population.4,8 von Willebrand disease (VWD) is the most common
inherited bleeding disorder, with a prevalence of 0.1% (deﬁned by
low levels of von Willebrand factor [VWF] and bleeding) in the general population9 but with a prevalence of 13% in patients with
HMB.10,11 More recently, low VWF levels, independent of a diagnosis of a bleeding disorder, have been shown to be a signiﬁcant risk
factor for HMB.12

Blood Assessment Chart score . 100 and low VWF, which was
deﬁned as having $2 values of VWF activity $ 30 and # 50 IU/dL
(as measured by VWF ristocetin cofactor assay [VWF:RCo] and/or
VWF glycoprotein IbM assay). Patients who did not meet these criteria or who were diagnosed with other bleeding disorders were
ineligible for the study. Adolescent females, seen in hematology clinics in participating centers managing patients with HMB, were
screened for study eligibility, eligible patients were approached for
study participation, and patients who consented to participate were
enrolled in the study. Clinical phenotype data were extracted prospectively from the patients and retrospectively by reviewing the
patients’ electronic medical records. Deidentiﬁed patient data from
each participating center were entered into the coordinating center’s electronic database; the data were maintained as conﬁdential
with access restricted to study investigators by means of password
protection. Baseline hemoglobin values, as well as both measures
of von Willebrand factor antigen (VWF:Ag), can be found in supplemental Table 1.

Common SNP analysis
Fisher’s exact tests were performed using PLINK to compare the
MAF of common and rare variants in cases and controls. SNPs
were dropped if the genotyping success rate was ,90% per SNP
or per individual, the Hardy-Weinberg equilibrium (P , 1 3 1026),
and MAF or missingness was ,0.05.

Gene burden and gene-set burden analysis

Results
Exome sequencing reveals excess of rare stop-gain/
stop-loss mutations in bleeding disorder genes and
rare pathogenic variants in anemia genes
Because rare likely pathogenic variants are necessarily enriched for
causal variants, we ﬁrst examined rare stop-gain/stop-loss and rare
ClinVar “pathogenic” variants in our sample. Among the 86 patients,
we observed 4 (4.6%) rare stop-gain or stop-loss mutations in
genes associated with bleeding or hematological diseases: CD36
(p.I337Vfs*10, NM_001371081), CPO (p.R184X, NM_173077),
VWF (p.E383X, NM_000552), and GP6 (p.X340R, NM_016363).
Variants in these genes are known to cause platelet glycoprotein IV
deﬁciency, hereditary coproporphyria, VWD, and bleeding disorder,
platelet type 11, respectively. In controls, there was 1 rare stop-gain
variant in CPO (0.15%). This difference was statistically signiﬁcant
(Fisher’s exact text, P 5 7.6 3 1024, odds ratio [OR], 31.8; 95%
conﬁdence interval [CI], 27.7-35.9). The patient we found with a
stop-gain mutation (p.E383X) in VWF had a frequency of this allele
in gnomAD of nearly 0, because only 1 instance of it was observed.
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We also pooled all rare (,1% in gnomAD) ClinVar “pathogenic”
variants present in cases that were in genes known to cause a dominant or recessive form of anemia or a disease with anemia as a
major symptom; 9.3% of cases and 4.2% of unrelated controls harbored such a variant, and this difference was signiﬁcant (Fisher’s
exact test, P 5 .04; OR, 2.3; 95% CI, 1.1-3.5) (Table 1). We performed the same comparison in genes involved in hemostasis and
platelet function. We found that 4.6% of cases and 1.4% of controls had rare ClinVar “pathogenic” variants in these genes (Fisher’s
exact test, P 5 .05; OR, 3.5; 95% CI, 2.5-4.5). This association
was driven by variants in cases in VWF (2), F2 (1) and LYST (1). All
signiﬁcant SNPs and genes remained signiﬁcant after correcting for
the presence of the D1472H variant. We compared our variants
with the ISTH VWDdb (Shefﬁeld database). None of the variants
that we found are listed as “segregates” in the database, but all are
listed, giving no speciﬁcity with regard to pathogenicity. Additionally,
there was only 1 patient within the cohort that had a VWF:RCo/
VWF:Ag ratio , 0.6 from the ﬁrst set of VWF:Ag measurements,
indicating that the cohort was not skewed toward lower VWF:RCo
levels because of the presence of this variant. To ensure these were
not false positive results, we also examined 5 “control” gene sets in
cases and controls including the GO terms “regulation of lipid metabolic processes,” “breast/ovarian cancer,” “microvascular complications from diabetes,” “epilepsy,” and “autism.” None of these were
signiﬁcant between cases and controls (.08 , P , .99).

Common and rare single SNP analyses
We tested for association with all common SNPs present in the exome
and genome data (.5% in gnomAD). Three common SNPs in linkage
disequilibrium in or downstream of FERMT2 (fermitin family member 2)
achieved genome-wide signiﬁcance in the common SNP analysis (P 5
2.9 3 1029; OR, 4.4; 95% CI, 3.0-7.8) (Figure 1). Although the MAF of
these SNP is 10% in non-Finnish Europeans in gnomAD, we found these
SNPs to be present in 24% of cases and 6% of controls. FERMT2 encodes a cytoskeletal protein that is a crucial regulator of integrin function.33
It is known to regulate hemostasis and is required for angiogenesis and
blood vessel homeostasis.34 Additionally, the SNPs that we found to be
associated with HMB are expression quantitative trait loci for FERMT2,
according to the Genotype Tissue Expression Project (https://www.
Table 1. List of genes with anemia as a primary disorder or
symptom in which a rare ClinVar “pathogenic” variant was
observed in cases
Gene

Disease association

Inheritance mode

ADAMTS13

Thrombotic thrombocytopenic purpura

Recessive

ANK1

Spherocytosis 1

Dominant

FANCA

Fanconi anemia, complementation group A

Recessive

G6PD

Nonspherocytic hemolytic anemia

Dominant

MVK

Mevalonic aciduria

Dominant

PKLR

Pyruvate kinase deﬁciency of red cells

Dominant

SLC46A1

Hereditary folate malabsorption

Recessive

TF

Atransferrinemia

Recessive
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To quantify the enrichment of rare nonsynonymous/splice-site variants and ClinVar “pathogenic” variants in HMB cases compared
with controls for each gene, we compared the collapsed MAF of
variants in cases and controls using a Fisher’s exact test using only
ﬁltered variants. Variants were ﬁltered by rareness and quality: (1)
max MAF in all populations , 0.01 in gnomAD exomes and
genomes, (2) genome quality . 20, (3) GATK variant quality score
recalibration of ‘PASS,’ (4) minimum sequencing depth of 8 reads
in each participant, and (5) allele balance . 0.3 and ,0.7. For statistical analysis of exome sequencing data, affected individuals were
compared with in-house exome controls. For individual gene association analyses, Fisher’s exact tests were performed using PLINK to
compare the collapsed MAF of rare variants in cases and controls.
Student t tests were performed using R to compare the quantitative
traits. For gene-set burden analyses, nonsynonymous/splice-site variants within a gene were collapsed to obtain the number of rare
(,1% in gnomAD) variants per gene. The numbers of variants
within groups of genes were then summed based on membership
within a given gene set and used as the dependent variable in a linear regression. Gene Ontology (GO) terms were obtained from
the UniProt Knowledgebase (http://www.uniprot.org/help/uniprotkb).
The exome-wide P-value cutoff was used in the gene burden analyses, because that is the number of independent tests (0.05/20 000
genes). Additionally, for our disease-associated gene-set burden
analyses, we created a disease-deﬁned set of genes involved in
anemia using Online Mendelian Inheritance in Man and UniProt disease descriptions by searching for the term “anemia.” For the bleeding disorder disease–deﬁned gene set we searched the same
databases for the terms “bleeding,” “platelet,” and “hemostasis.”

This variant was previously identiﬁed in 1 patient with VWD.32 This
variant is not listed in ClinVar but is likely to be the cause of the
HMB in that individual and also may be contributing to any VWD
phenotype that they have.

binding site associated antigen 9) is primarily produced by macrophages in hematopoietic tissue and has a crucial role in controlling
erythropoiesis.35 TTC18 (a.k.a. CFAP70 [cilia and ﬂagella associated
protein 70]) is expressed in the cilia of glandular cells in fallopian
tube, endometrium, and respiratory tract36 (http://www.proteinatlas.
org), and TCN1 (transcobalamin 1) is highly expressed in granulocytes,36 which have been identiﬁed as critical determinants of uterine
bleeding and tissue remodeling in a mouse menstruation model.37
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Figure 1. QQ plot of the P values for common SNPs. Three SNPs in
FERMT2 achieved genome-wide signiﬁcance (yellow oval).

gtexportal.org/home/), further supporting their potential functional role in
the phenotype.
We also discovered SNPs in 3 additional genes with P values reaching exome-wide signiﬁcance (Figure 2). EBAG9 (estrogen receptor
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Figure 2. Manhattan plot of the P values for common SNPs. Three SNPs in FERMT2 achieved genome-wide signiﬁcance (purple line), whereas SNPs in EBAG9,
TTC18, and TCN1 achieved exome-wide signiﬁcance (green line).
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Only coding variants that caused non-sense, splice-site, missense,
or insertion/deletion mutations that were rare (deﬁned as ,1% in
gnomAD) were included in the analysis. This ﬁltering strategy was
selected to enrich for mutations that are very rare and most likely to
be deleterious. Using a gene burden analysis, we compared the
genome-wide frequency of rare coding variants in HMB cases and
controls. An increased burden of rare variants that surpassed
exome-wide signiﬁcance was seen in 10 genes (Table 2). The top
hit in the results was CFB (complement factor B), which achieved
exome-wide signiﬁcance and was the only gene in this analysis to
also achieve genome-wide signiﬁcance (P 5 3.0 3 1028). This
gene encodes for a component of the alternative pathway of complement activation. The collapsed MAF (cMAF) for all rare variants in
CFB was 0.02 in cases (n 5 86) and 0.0 in controls (n 5 660).
Rare variants in this gene have been associated with atypical hemolytic uremic syndrome,38,39 which is characterized by microangiopathic hemolytic anemia and thrombocytopenia, as well as acute
renal failure.40

Table 2. Gene burden analysis results for genes achieving exome-wide signiﬁcance
Gene

Gene name

cMAF affected

Cases, n

cMAF unaffected

Controls, n

P

CFB

Complement factor B

0.023

4

0.000

0

3.03 3 1028

DNASE2

Deoxyribonuclease 2, lysosomal

0.041

7

0.004

5

3.53 3 1027

FGFRL1

Fibroblast growth factor receptor-like 1

0.041

7

0.004

5

3.53 3 1027

Neuralized E3 ubiquitin protein ligase 3

0.116

20

0.034

45

7.05 3 1027

CCL5

C-C motif chemokine ligand 5

0.017

3

0.000

0

1.62 3 1026

IL5RA

Interleukin 5 receptor subunit a

0.017

3

0.000

0

1.62 3 1026

KCNK18

Potassium 2 pore domain channel subfamily k member 18

0.017

3

0.000

0

1.62 3 1026

TBCCD1

TBCC domain containing 1

0.017

3

0.000

0

1.62 3 1026

TBL1X

Transducin b like 1X-linked

0.029

5

0.002

3

6.11 3 1026

VWF

von Willebrand factor

0.111

19

0.036

47

7.31 3 1026

The second most signiﬁcant hit in our results was DNASE2 (deoxyribonuclease 2, lysosomal), which achieved exome-wide signiﬁcance
(P 5 3.5 3 1027). The cMAF for all rare variants in DNASE2 was
0.04 in cases compared with 0.004 in controls. This gene encodes
a protein that mediates the breakdown of DNA during erythropoiesis
and apoptosis. Patients with complete loss of function of this gene
were observed to have severe anemia and thrombocytopenia.41
Because it has been shown that patients with low VWF have an
increased rate of rare variants in VWF,42 it is perhaps expected that
VWF was also signiﬁcant in the gene burden analysis. There were
19 cases (22%) and 47 controls (7%) with $1 rare nonsynonymous variant in VWF (P 5 7.3 3 1026).

Rare variants in hematologically relevant pathways
collectively inﬂuence HMB risk
Although some genes achieved exome-wide signiﬁcance in the
gene burden analyses (Table 2), we used our previously developed
pathway burden analysis framework43 that, unlike some methods,44
preserves power by using data from all genes, not only those with
signiﬁcant single-gene associations. With this method, variants are
ﬁrst collapsed at the gene level and then by GO term membership.
Exome-wide pathway burden analysis yielded a strong association
between HMB and novel variants in genes within the GO terms
“oxygen transporter activity,” “hemoglobin complex,” “platelet degranulation,” “positive regulation of erythrocyte differentiation,” and
platelet a granule lumen” (Table 3). These terms are not mutually
exclusive; in fact, some have a signiﬁcant amount of overlap.
Notably, these and several other top associated GO terms are
highly correlated, often consisting of gene lists that are subsets of
one another. For example, nearly all of the genes in the term

“hemoglobin complex” are included in the term “oxygen transporter
activity.”

Discussion
It is estimated that up to 30% of women experience HMB, and it
accounts for two thirds of all hysterectomies.45 Many systemic disruptions of hemostasis, such as liver disease and hypothyroidism,
are well-described causes of HMB,10 yet 50% of women with hysterectomies resulting from HMB do not have the underlying cause
identiﬁed.46 Thus, it is clinically important to understand the underlying causes of HMB. Although it is known that bleeding disorders,
such as VWD, occur more frequently in this subpopulation than in
the overall population, IDA is a common, but underappreciated,
complication in adolescents with HMB.2 The anemia is a direct
result of the excessive blood loss during menses and occurs when
iron depletion is severe enough to suppress erythropoiesis.47
Genetic causes of anemia do not necessarily imply a mechanism
beyond bleeding. In many cases the underlying biological mechanism is unknown and could be a presdisposition to bleeding.

HMB is associated with rare and common variants
in anemia genes
We performed several types of whole-exome analyses on 86 HMB
cases compared with our in-house controls. We focused primarily
on rare variant analyses, because, as a class, rare variants (deﬁned
as ,5% population frequency) constitute the majority of genetic
variation and are 4 times more likely to be deleterious.48 In single
SNP rare variant and rare variant gene burden analyses, HMB cases
had signiﬁcantly more rare variants in genes known to cause different subtypes of anemias than did controls. Additionally, common
variant analysis revealed an association with 1 gene that is known

Table 3. Relevant results of gene-set burden analyses of patients with HMB
Freq Cases

Freq Unaffected

OR

P

Oxygen transporter activity

0.047

0.003

14.13

2.5 3 10210

Hemoglobin complex

0.047

0.004

12.1

1.6 3 1029

Platelet degranulation

0.139

0.048

Positive regulation of erythrocyte differentiation

0.023

0.001

Platelet a granule lumen

0.105

0.031

Gene Ontology term/KEGG pathway

3.205
20.74
3.658

Freq, frequency; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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to contribute to anemia. That the HMB patients do not have known
diagnoses of these Mendelian disorders suggests that the variants
we identiﬁed could be causing less severe or incompletely penetrant forms of anemia.

Second, the 2 most signiﬁcant genes from the gene burden analysis
are directly linked to anemia. As previously mentioned, rare missense mutations in CFB are associated with atypical hemolytic uremic syndrome.38,39 Biallelic mutations in DNASE2 have been
associated with a loss of DNase II endonuclease activity, causing
severe neonatal anemia and thrombocytopenia, among other symptoms.41 This loss of DNase II induces interferon signaling, inhibiting
macrophages from destroying nuclear DNA expelled from erythroid
precursor cells. Increased erythroblasts in peripheral blood are
observed, suggestive of ineffective erythropoiesis.41 This phenotype
is also seen in mice, because DNase II–null mice accumulate undigested DNA in the lysosomes of macrophages, activating the production of type 1 interferon and resulting in lethal perinatal
anemia.49,50 Because the patients with HMB in our study did not
appear to have biallelic loss of DNASE2, it is possible that having
haploinsufﬁciency may cause a milder anemia.
Lastly, common variant analysis revealed an association with
EBAG9, which induces apoptosis in normal human erythroid
progenitor cells.35 EBAG9 has been detected in monocytes and
macrophages. When macrophages were stimulated with lipopolysaccharide, expression of the protein increased, and cell death of
erythroid progenitor cells was induced by this increased expression.
It has been suggested that erythropoiesis is negatively regulated, in
part, by macrophages through the production of EBAG9, contributing to the pathogenesis of anemia in patients with inﬂammatory
disorders.51
It was recently shown that elevated hematocrit is associated with
increased platelet accumulation at the site of injury in mice and
human, establishing the role of red cells in normal hemostasis and
further underscoring the association of anemia with increased
bleeding.52

Rare and common variants in bleeding genes,
including VWF, in HMB patients
We also replicate what other investigators have noted in patients
with HMB: an enrichment of pathogenic variants in genes known to
cause bleeding disorders.10-12 We found 4 rare stop-gain/stop-loss
mutations in our cases. One of these was a rare stop-gain mutation
in VWF that has not been seen in gnomAD. This mutation may be
contributing to the undiagnosed VWD in that patient. Two of these
mutations are in genes that are known to cause platelet deﬁciency
(CD36) and platelet-type bleeding disorder (GP6). The last was a
stop-gain mutation in CPO, a gene that causes a type of hereditary
25 JANUARY 2022 • VOLUME 6, NUMBER 2

Limitations
Although 86 patients are sufﬁcient for detecting an association with
variants of modest effect size, we recognize that our study is underpowered to detect variants of smaller effect sizes. We evaluated the
clinical phenotypes that we ascertained to associate them with
genetic variants, but there was too little variation in the laboratory
values to identify any associations. This is due to the fact that all
patients have the HMB clinical phenotypes, regardless of any differences in the underlying reason for the HMB. In the future we hope
to sequence more patients to further ﬁne-tune the associations, as
well as to replicate these associations in other similarly phenotyped
data sets.

Conclusions
We present the ﬁrst whole-exome sequencing results of patients
with HMB, as well as their comparison with control exomes. In addition to observing an excess of rare nonsynonymous variants in
genes involved in several bleeding disorders, we observed excess
variants in genes causing anemias and disorders with anemia as a
symptom. Although most of these patients may not have the full disorder associated with variants in that gene, they may simply have a
milder version due to incomplete penetrance of the variants, as well
as potential interactions with variants in other genes that are needed
to cause the severe form of the disorder. Our ﬁndings need
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First, we observed signiﬁcantly more rare ClinVar “pathogenic” variants in 8 genes associated with varying types of anemias in cases
than in controls. A subset of these genes causes dominant forms of
anemia, suggesting that it is possible that at least a subset of
patients with these rare pathogenic variants may actually have
undiagnosed disease. In these patients, the anemia may precede
the HMB and, thus, would be exacerbated by the blood loss.
Patients with variants in the genes causing recessively inherited anemias may also have milder forms of the disease if they have 1 functional copy of the gene.

porphyria. Porphyrias are a group of inborn errors of heme biosynthesis.53 We also observed more rare ClinVar “pathogenic” variants
in hemostasis and platelet function genes in cases vs controls,
including 2 people with the same rare ClinVar “pathogenic” variant
in VWF (P1266Q, NM_000552), 1 variant in F2, and 1 variant in
LYST. The variant in F2 (c.*97G.A, NM_000506.5) has been
associated with prothrombin-related thrombophilia,54 and the variant
in LYST (p.R1563H, NM_000081.3) has been shown to be associated with Chediak-Higashi syndrome.55,56 Coagulation defects are
1 of the known symptoms of Chediak-Higashi syndrome.57 Although
the VWF variant that we found has been observed in patients with
type 2 VWD,58 the patients with this variant had a normal multimer
pattern and normal plasma and platelet VWF levels. Of the 2
patients with P1266Q_NM_000552, 1 patient had an additional
variant in VWF (p.P2297L_NM_000552). However, there were also
3 controls with the P1266Q variant, suggesting that it is not pathogenic on its own. VWF was also signiﬁcant in the rare variant gene
burden analysis, and common variant analysis showed an association with FERMT2, which is involved in the regulation of hemostasis,
angiogenesis, and blood vessel homeostasis.34 This gene encodes
kindlin-2, a widely distributed cytoskeletal protein that is involved in
integrin activation. Its absence is embryonically lethal in mice and
causes severe developmental defects in zebraﬁsh.59 Even partial
reduction of kindlin-2 in mice resulted in fewer blood vessels,
whereas the vessels that form lack smooth muscle cells and are
thinner and shorter than normal.34,59 Kindlin-2 is present in platelets,60 and kindlin-2–knockdown mice had prolonged bleeding and
vascular occlusion times as a result of the suppression of platelet
aggregation caused by the elevated expression of 2 enzymes
(CD39, CD73) on endothelial cells.34 Therefore, an enrichment of
variants in FERMT2 in cases is consistent with what is known about
the pathophysiology of this gene and its encoded protein. Additionally, the gene-set burden analysis revealed an enrichment of rare variants in cases in several pathways relevant to hemostasis.

validation in larger cohorts. This work may begin to shed some light
on the large proportion of patients with HMB who do not have a
cause for their symptoms. Eventually, identifying these patients with
HMB and with these risk variants may improve risk stratiﬁcation and
patient outcomes.
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